Fig 1.
Flowchart of patient inclusion and exclusion.
Abbreviations: ART–Antiretroviral treatment.
Table 1.
Characteristics of study subjects stratified by viremia category.
Patients are categorized according to their highest viremia category during the study.
Fig 2.
Flowchart illustrating patients changing viremia categories during follow-up.
The top of the figure represents viremia categories at inclusion and the lower part shows how patients changed categories during the follow-up time. Reclassification was only made to higher viremia strata, and the reclassified subjects remained in that strata for the remaining follow-up period (unless progression to a higher viremia stratum occurred). Abbreviations: PSV–permanently suppressed viremia; LLV-I–low-level viremia 50–199 copies/mL; LLV-II–low-level viremia 200–999 copies/mL; HLV–high-level viremia.
Fig 3.
Extended Kaplan-Meier estimate for virological failure, stratified by viremia category (n = 992).
Abbreviations: PSV–permanently suppressed viremia; LLV-I–low-level viremia 50–199 copies/mL; LLV-II–low-level viremia 200–999 copies/mL; HLV–high-level viremia.
Table 2.
Crude and adjusted hazard ratios for virologic failure and all-cause death stratified by viremia category.
Adjusted for sex, age at inclusion, mode of transmission (IDU vs others), time of inclusion and CD4 nadir. Results are expressed as [HR (95% CI)].
Table 3.
Cause of death in study subjects, in total and stratified by viremia category.
Results are expressed as [n (%)].
Fig 4.
Extended Kaplan-Meier plot for death stratified by viremia category (n = 1015).
Abbreviations: PSV–permanently suppressed viremia; LLV-I–low-level viremia 50–199 copies/mL; LLV-II–low-level viremia 200–999 copies/mL; HLV–high-level viremia.